Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix has provided a corporate update, highlighting significant advancements with NBTXR3 for treating head and neck cancer. The first European patient has been randomized in the pivotal NANORAY-312 study, with U.S. and Asia site activations expected to follow. The company aims to establish a registration pathway for NBTXR3 in combination with anti-PD-1 therapy based on positive initial data from ongoing studies. Financially, Nanobiotix has extended its operating runway into Q2 2023 through improved operational efficiencies and capital optimization.
Nanobiotix announced the first patient enrollment in the pivotal NANORAY-312 phase III study assessing radiotherapy-activated NBTXR3, with or without cetuximab, for elderly patients with locally advanced head and neck squamous cell carcinoma. This study aims to prove the superiority of NBTXR3 over standard treatments. The US FDA has granted Fast Track designation for NBTXR3 in this patient group, allowing for faster review and potential accelerated approval.
Nanobiotix, a late-stage clinical biotechnology company, announced participation in three virtual investor conferences in
- Oddo BHF Forum 2022: January 6-11, 2022
- H.C. Wainwright Bioconnect Conference: January 10-13, 2022
- Biotech Showcase™ 2022: January 17-19, 2022
Nanobiotix has reported its voting rights and share count as of November 30, 2021. The company has 34,825,872 shares outstanding, with a total of 36,003,389 voting rights (gross) and 35,985,166 voting rights (net). This information aligns with regulatory requirements set by the French Financial Markets Authority.
Nanobiotix, listed on both Euronext Paris and Nasdaq, specializes in innovative therapeutic approaches in biotechnology, focusing on oncology and has market authorization for its lead candidate, NBTXR3.
NANOBIOTIX (NASDAQ: NBTX), a late-stage biotechnology company focusing on innovative cancer treatments, announced participation by CEO Laurent Levy in a virtual fireside chat at the Evercore ISI HealthCONx Conference on December 2, 2021, at 1:00 PM EST. The live audio webcast will be accessible on the company’s website, with an archived recording available for 90 days. NANOBIOTIX, founded in 2003 and headquartered in Paris, is known for its physics-based therapeutic approaches and has market authorization for its product NBTXR3 in Europe.
NBTXR3, developed by Nanobiotix, shows promising preclinical results presented at the 36th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC). The data indicate that radiotherapy-activated NBTXR3 enhances CD8+ T cell infiltration and modulates the T cell receptor repertoire, suggesting improved immune priming. Additionally, the combination of NBTXR3 with anti-PD-1, anti-LAG3, and anti-TIGIT substantially elevated anti-tumor immune response activities. These findings underscore potential advancements in combination therapies for solid tumors.
Nanobiotix announced its latest regulatory update as of October 31, 2021, reporting a total of 34,825,872 shares outstanding. The gross total number of voting rights is 36,003,389, while the net total is 35,983,625. This update is in compliance with the French Commercial Code and aims to ensure transparency in shareholder communications. Established in 2003, the company focuses on innovative therapeutic solutions in oncology, with its lead candidate NBTXR3 already authorized in Europe for treating soft tissue sarcoma.
Nanobiotix, a late-stage biotechnology company specializing in innovative cancer treatments, announced CEO Laurent Levy's participation in a fireside chat at the Jefferies London Healthcare Conference. Scheduled for November 16, 2021, at 3:40 PM GMT/10:40 AM EST, the event will be live-streamed on the company's website. Established in 2003, Nanobiotix focuses on physics-based therapies and holds over 30 patents. Its lead product, NBTXR3, is authorized in Europe for soft tissue sarcoma under the brand name Hensify®.
Nanobiotix has released first survival data from its NBTXR3 program at the ASTRO 2021 Annual Meeting. In a group of 41 elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC), the median overall survival (mOS) was 18.1 months and median progression-free survival (mPFS) was 10.6 months. The best objective response rate (ORR) was 85.4%, with a complete response rate (CRR) of 63.4%. These positive findings support future phase III trials aimed at this challenging patient group.
Nanobiotix (NASDAQ: NBTX) reported progress in its oncology clinical programs, highlighting published preclinical data in the
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
